World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
36577
World Ranking
11181
National Ranking
5751

Overview

Maurie Markman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and molecular biology fields, with substantial contributions to cancer research and reproductive medicine.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Markman's work covers several subfields, notably:

  • Cancer Research
  • Reproductive Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Epidemiology

The main research topics they address are:

  • Cancer Genomics and Diagnostics
  • Ovarian cancer diagnosis and treatment
  • Renal cell carcinoma treatment
  • Pancreatic and Hepatic Oncology Research
  • Intraperitoneal and Appendiceal Malignancies
  • Endometrial and Cervical Cancer Treatments
  • Molecular Biology Techniques and Applications

Maurie Markman has contributed to numerous scientific publications across various venues. Frequent publication outlets include:

  • Journal of Clinical Oncology
  • Gynecologic Oncology Reports
  • Gynecologic Oncology
  • Future Virology
  • Cancer Research

Recent papers by Markman highlight topics in ovarian and pancreatic cancers and include:

  • What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer, 2022, Gynecologic Oncology
  • Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery, 2020, Gynecologic Oncology Reports
  • Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network, 2022, Journal of Clinical Oncology
  • Racial differences in the mutational landscape of serous endometrial cancer, 2022, Journal of Clinical Oncology
  • 36 Mutational landscape of low-grade serous carcinoma of the ovary, 2022, Gynecologic Oncology Reports

Their collaborative network includes frequent co-authors such as:

  • Vicki Doctor
  • Amber Moran
  • Julian C. Schink
  • Julia A. Elvin
  • Natalie Godbee

Best Publications

  • Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

    Maurie Markman;Brian N. Bundy;David S. Alberts;Jeffrey M. Fowler

  • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    M Markman;R Rothman;T Hakes;B Reichman

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers

    Yan Xu;Zhongzhou Shen;Donald W. Wiper;Minzhi Wu

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Clinical Features of Hypersensitivity Reactions to Carboplatin

    Maurie Markman;Alexander Kennedy;Kenneth Webster;Paul Elson

  • Paclitaxel in cancer therapy.

    Tarek M Mekhail;Maurie Markman

  • Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

    Bryan T.J. Hennessy;Kirsten M. Timms;Mark S. Carey;Alexander Gutin

  • Second-line treatment of ovarian cancer.

    Maurie Markman;Michael A. Bookman

  • Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    M Markman;E Rowinsky;T Hakes;B Reichman

  • Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

    Howard D. Homesley;Virginia Filiaci;Maurie Markman;Pincas Bitterman

  • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    Maurie Markman;John Blessing;Stephen C. Rubin;Joseph Connor

  • Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

    Maurie Markman;James Hall;Daniel Spitz;Sheldon Weiner

  • Long-Term Survival of Advanced Refractory Ovarian Carcinoma Patients with Small-Volume Disease Treated with Intraperitoneal Chemotherapy

    Stephen B. Howell;Soloman Zimm;Maurie Markman;Ian S. Abramson

  • Intraperitoneal antineoplastic drug delivery: rationale and results

    Maurie Markman

  • RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION

    M Markman;W Hoskins

  • Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

    Maurie Markman;Jonathan Markman;Kenneth Webster;Kristine M. Zanotti

  • Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

    Eric Winer;Julie Gralow;Lisa Diller;Beth Karlan

  • Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

    M Markman;B Reichman;T Hakes;W Jones

Frequent Co-Authors

William J. Hoskins
William J. Hoskins Memorial Sloan Kettering Cancer Center
Stephen C. Rubin
Stephen C. Rubin University of Pennsylvania
Stephen B. Howell
Stephen B. Howell University of California, San Diego
Richard R. Barakat
Richard R. Barakat Northwell Health
David S. Alberts
David S. Alberts University of Arizona
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Lynn M. Schuchter
Lynn M. Schuchter University of Pennsylvania
Yoshihiko Maehara
Yoshihiko Maehara Kyushu University
Raymond Sawaya
Raymond Sawaya The University of Texas MD Anderson Cancer Center
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA involves various educational routes, including flexible online options for those seeking advanced nursing or entry-level roles. Accelerated online programs are gaining popularity, allowing students to earn credentials faster and join the healthcare workforce sooner.

For nurses aiming to reach the highest clinical degrees, several universities offer the shortest post master's DNP program, letting experienced nurses complete their Doctor of Nursing Practice in less time. Additionally, various DNP online programs are designed for flexibility and accessibility, ideal for working professionals balancing studies and career.

If you’re interested in psychiatric nursing, some schools provide the shortest post master's PMHNP online programs, preparing nurses for specialized roles in mental health in record time.

Those starting out can consider entry-level options, such as a LPN program online, which enables rapid entry into the nursing field.

With these diverse choices, prospective healthcare professionals can find pathways that match their personal goals, timelines, and learning preferences.

Best Scientists Citing Maurie Markman

Trending Scientists

Recently Published Articles